Drummond urges White House offer Medicare coverage for Alzheimer’s treatment

Attorney General Gentner Drummond is heading a coalition of more than two dozen attorney’s general in pushing for the Centers for Medicare and Medicaid Services to provide coverage for a drug approved by the FDA, that has proven to delay the progression of Alzheimer’s Disease.

Drummond requested that CMS provide full and unrestricted Medicare coverage for FDA-approved Alzheimer’s treatments.

In a news release Drummond said, “”The more than 6 million Americans who are living with Alzheimer’s deserve equal access to FDA-approved medications. The Biden administration should be fighting for these patients and their families. It is critical that we ensure these vulnerable patients can receive treatments that are recommended by their doctors.”

The treatment specified by attorneys general in the letter is FDA-approved monoclonal antibodies directed against amyloid to help Alzheimer’s patients. Currently, CMS will only cover mAbs when it is administered through clinical trials or other studies.